This CTD dossier owner and manufacturer was founded in 2007 and has two manufacturing facilities strategically located in India. They boast over 1,800 products spanning a range of therapeutic areas, including those focused on dermatology, pain management, and possibly central nervous system disorders based on the listed divisions. The company produces both prescription medications and over-the-counter drugs, utilizing diverse dosage forms such as tablets and capsules. They maintain a strong national network for distribution and a global presence. GMP certifications are likely held due to their focus on quality manufacturing practices.

This company, established in the early 1980s in South Asia, has a strong focus on innovative drug delivery systems (NDDS). With over three decades of experience, it boasts multiple globally patented technologies and has grown into a significant player in the pharmaceutical sector. The company's portfolio includes a diverse range of products in therapeutic areas like pain management, gynecology, and critical care. It also develops nutraceuticals and nutritional supplements. The company offers a variety of dosage forms, including oral, injectable, and potentially liquid forms. They manufacture products in state-of-the-art facilities, adhering to stringent GMP standards. These facilities hold approvals from international regulatory agencies, including WHO, PIC/S, and ANVISA, and are currently pursuing EU and USFDA certifications. The company's footprint extends across key regions, including Asia, Africa, Latin America, and the CIS. This global reach is further strengthened by a dedicated regulatory, operational, marketing, and business development teams. The company actively engages in licensing agreements with multinational and regional players, demonstrating its commitment to innovation and partnership.